Clinical trials: Placebo Response
Rheumatoid Arthritis
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
- Trial name
- NCT00152386
- Testing
- Certolizumab pegol (CDP870)
- Where
- 76 sites in United States, Argentina and 11 more
- Volunteers
- 950 people
- Sponsor
- UCB Pharma
Healthy
A Device Study in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given.
- Trial name
- NCT04848402
- Testing
- On-Body Delivery System (OBDS)/Multiple Bolus Injector, Single Auto Injector
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Healthy Volunteer
Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males
This is a phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (SAD) and multiple ascending doses (MAD) of VNA-318 in…
- Trial name
- NCT06721091
- Testing
- VNA-318
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- VANDRIA
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
Depressive Disorder
The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression
The purpose of this study is to assess whether the antidepressant effect from intravenous (IV) ketamine treatment can be maintained by minocycline compared to placebo after IV ketamine treatment is stopped.
- Trial name
- NCT01809340
- Testing
- Minocycline, Ketamine
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS) for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate…
- Trial name
- REASSURE2 (NCT01770379)
- Testing
- Secukinumab (AIN457)
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects
Study to determine the effect of a single dose BIRB 796 BS on systemic inflammatory responses induced by endotoxin in healthy humans
- Trial name
- NCT02211170
- Testing
- BIBR 796 BS, low dose, BIBR 796 BS, high dose, Lipopolysaccharide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
A study with an 8 week open label phase study followed by a year long placebo controlled maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy…
- Trial name
- NATRUL-4 (NCT01882764)
- Testing
- HMPL-004
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Hutchison Medipharma Limited
Renal Hemodynamics
Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide
This phase 1 study is an 8-day treatment period, randomized, controlled, double-blind, 3 parallel-groups, monocentric study. The primary objective is to evaluate the effect of naproxcinod on the renal function when…
- Trial name
- NCT00909519
- Testing
- naproxcinod, Naproxen, furosemide
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- NicOx
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Nipah Virus Infection
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- Trial name
- NCT05178901
- Testing
- PHV02
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Insomnia, Depressive Disorder, Major
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
- Trial name
- NCT00368030
- Testing
- Eszopiclone
- Where
- 65 sites in United States
- Volunteers
- 545 people
- Sponsor
- Sumitomo Pharma America, Inc.
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
Healthy
A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
An endotoxin challenge will be administered to healthy subjects to induce production of inflammatory markers. An investigational drug or placebo will be administered prior to the endotoxin challenge to assess the effect of the…
- Trial name
- POM (NCT01965600)
- Testing
- PF-06282999, LPS
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics
Pain
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.
- Trial name
- NCT00159640
- Testing
- PD-217,014
- Where
- 32 sites in Australia, Canada and 4 more
- Volunteers
- 315 people
- Sponsor
- Pfizer
Cancer
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
- Trial name
- NCT00562913
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Bayer
Rheumatoid Arthritis
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
This randomized, double-blind, placebo-controlled study will use Magnetic Resonance Imaging (MRI) to assess the efficacy of tocilizumab plus non-biological DMARD in patients with moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01034397
- Testing
- tocilizumab [RoActemra/Actemra], non-biological DMARDs
- Where
- 11 sites in Portugal
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche